{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:16:16Z","timestamp":1748405776028,"version":"3.41.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women &gt;30 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16\/18 genotyping at 3-year intervals. All HPV 16\/18-positive cases and\/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16\/18-positive cases and LSILs were graded using p16\/Ki67 dual-stain cytology, and positive cases were sent for colposcopy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 2409 patients were included. After the first combined screening (year \u2018zero\u2019) visit, 7.4% of women were HPV-positive and 2.0% were HPV16\/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28\/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year \u2018three\u2019), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16\/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005\u2264\u20050.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The addition of HPV DNA testing with selective genotyping of HPV16\/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000844","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:11:17Z","timestamp":1695748277000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening?"],"prefix":"10.1097","volume":"33","author":[{"given":"Ji\u0159\u00ed","family":"Sl\u00e1ma","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Neonatology, General University Hospital, 1Medical Faculty, Charles University, Prague"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Dvo\u0159\u00e1k","sequence":"additional","affiliation":[{"name":"Center for Outpatient Gynaecology and Primary Care, Brno"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark\u00e9ta","family":"Trnkov\u00e1","sequence":"additional","affiliation":[{"name":"Unilabs Pathology, Prague"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ale\u0161","family":"Sk\u0159iv\u00e1nek","sequence":"additional","affiliation":[{"name":"G-Center, Olomouc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol\u00edna","family":"Hrabcov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Ovesn\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Nov\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/djn099","article-title":"Screening- preventable cervical cancer risks: evidence from a nationwide audit in Sweden.","volume":"100","author":"Andrae","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ijc.33189","article-title":"The European response to the WHO call to eliminate cervical cancer as a public health problem.","volume":"148","author":"Arbyn","year":"2021","journal-title":"Int J Cancer"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.pvr.2019.100170","article-title":"Towards the global elimination of cervical cancer.","volume":"8","author":"Canfell","year":"2019","journal-title":"Papillomavirus Res"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1470-2045(20)30729-4","article-title":"WHO launches strategy to accelerate elimination of cervical cancer.","volume":"22","author":"Das","year":"2021","journal-title":"Lancet Oncol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.","volume":"102","author":"Kj\u00e6r","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/dji115","article-title":"Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.","volume":"97","author":"Leyden","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ajcp\/aqy073","article-title":"Clinical utility of cintec PLUS triage in equivocal cervical cytology and human papillomavirus primary screening.","volume":"150","author":"McMenamin","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"e019171","DOI":"10.1136\/bmjopen-2017-019171","article-title":"\u2018It has saved thousands of lives, so why change it?\u2019 content analysis of objections to cervical screening programme changes in Australia.","volume":"8","author":"Obermair","year":"2018","journal-title":"BMJ Open"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ypmed.2016.09.034","article-title":"Impact of provider-patient communication on cancer screening adherence: a systematic review.","volume":"93","author":"Peterson","year":"2016","journal-title":"Prev Med"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2011.02.033","article-title":"Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki- 67 Dual-stained cytology.","volume":"121","author":"Petry","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1016\/j.vaccine.2018.06.044","article-title":"A report on the status of vaccination in Europe.","volume":"36","author":"Sheikh","year":"2018","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"R17-20250527","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening.","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J Clin Virol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program.","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-155-10-201111150-00376","article-title":"Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. preventive services task force.","volume":"155","author":"Whitlock","year":"2011","journal-title":"Ann Intern Med"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cyt.12300","article-title":"Bethesda 2014: improving on a paradigm shift.","volume":"26","author":"Wilbur","year":"2015","journal-title":"Cytopathology"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","article-title":"Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial.","volume":"144","author":"Wright","year":"2017","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:01:04Z","timestamp":1748361664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000844","relation":{},"ISSN":["0959-8278"],"issn-type":[{"type":"print","value":"0959-8278"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}